Haemophilia management: Time to get personal?

T. E. Howard*, C. Yanover, J. Mahlangu, A. Krause, K. R. Viel, C. K. Kasper, K. P. Pratt

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


The possibility of alloimmunization in patients receiving protein replacement therapy depends on (at least) three risk factors, which are necessary concomitantly but insufficient alone. The first is the degree of structural difference between the therapeutic protein and the patient's own endogenous protein, if expressed. Such differences depend on the nature of the disease mutation and the pre-mutation endogenous protein structure as well as on post-translational changes and sequence-engineered alterations in the therapeutic protein. Genetic variations in the recipients' immune systems comprise the second set of risk determinants for deleterious immune responses. For example, the limited repertoire of MHC class II isomers encoded by a given person's collection of HLA genes may or may not be able to present a 'foreign' peptide(s) produced from the therapeutic protein - following its internalization and proteolytic processing - on the surface of their antigen-presenting cells (APCs). The third (and least characterized) variable is the presence or absence of immunologic 'danger signals' during the display of foreign-peptide/MHC-complexes on APCs. A choice between existing therapeutic products or the manufacture of new proteins, which may be less immunogenic in some patients or patient populations, may require prior definition of the first two of these variables. This leads then to the possibility of developing personalized therapies for disorders due to genetic deficiencies in endogenous proteins, such as haemophilia A and B. [Correction made after online publication 11 July 2011: several critical corrections have been made to the abstract].

Original languageEnglish
Pages (from-to)721-728
Number of pages8
Issue number5
StatePublished - Sep 2011
Externally publishedYes


  • Antigen-presentation repertoire
  • Factor VIII inhibitor
  • HLA class II
  • Haemophilia A
  • Non synonymous-SNPs
  • Pharmacogenetics


Dive into the research topics of 'Haemophilia management: Time to get personal?'. Together they form a unique fingerprint.

Cite this